LAS VEGAS, Feb. 9 /PRNewswire-FirstCall/ -- NetImpact Holdings, Inc. (OTC Pink Sheets: NTHD) today announced that scientists, including biochemists and bioengineers, are investigating the possibility of using NetImpact's MDS200 to detect Mad Cow disease. Scientists will place samples of the cow's blood or neural tissue into the MDS200 to further develop and test the system to identify the disease. Using cow's blood avoids slaughtering the animal to access brain stem tissue or slaughtering herds of cows to stop the spread of the disease.
The brain stem tissue test produces accurate results in about one week.
NetImpact expects the MDS200 test to produce accurate results in a matter of hours.
NetImpact anticipates positive reports from the scientific team. The Company plans to move their lab in a box to market without delay and is pursuing partnerships with other firms and investment capital groups in the U.S., Canada, England, Japan and Australia.
The MDS200 lab in a box is a breakthrough technology for disease detection. Currently used on solids, gases and fluids, it is capable of automatic preparation and testing of difficult and dirty samples containing cell, protein, nucleic acid and chemical analytes. About the size of a small suitcase, the MDS200 is a rugged portable laboratory designed for use in remote areas with non-existent or scarce laboratory facilities and readily carried from location to location. Test results are displayed on the unit's LED and can be sent via satellite or dial up connections. Once a sample has been placed in the lab in a box the processing is spontaneous. Operating an MDS200 does not require a trained lab technician.
About NetImpact Holdings, Inc.
NetImpact Holdings, Inc. is a technology-to-market company focusing on the installation, restructuring and management of global healthcare and medical delivery systems. Through acquisitions and extensive access to international/U.S. distribution networks, NetImpact specializes in presenting technology that will assist in the improvement of productivity, applications development, and technology transfer in developing countries. The Company's NetCare Division, Medical and Diagnostic Devices Division, and Neurowave Division are moving their technologies, products and services to an awaiting market.
Safe Harbor Statement
The statements in this release that are not historical facts are forward- looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. NetImpact Holdings, Inc. intends that such forward-looking statements be subject to the safe harbors created thereby. These forward-looking statements include predictions, estimates and other statements that involve a number of risks and uncertainties any, or all, of which could cause actual results to differ materially from any future performance suggested herein. While this outlook represents NetImpact Holdings, Inc.'s current judgment on the future direction of the business, such risks and uncertainties may individually, or mutually, impact the matters herein described, including but not limited to product acceptance, the economy, competition, governmental actions, results of litigation, technological and/or other factors, which are outside the control of NetImpact Holdings, Inc. as well as those risks and uncertainties detailed in the Company's Security and Exchange Commission filings.
Emerson Gerard Associates
NetImpact Holdings, Inc.